ライフサイエンスコーパス: central obesity

1 , vitamin D and C-reactive protein, and less central obesity).

2 of overall obesity, and waist-hip ratio for central obesity.

3 e tissues in IGT(+) directly associated with central obesity.

4 disease (CHD) such as insulin resistance and central obesity.

5 ictive power of overall obesity with that of central obesity.

6 style factors that favour the development of central obesity.

7 of its association with body mass index and central obesity.

8 of blood pressure than did other measures of central obesity.

9 tion, and distribution, and in excess, cause central obesity.

10 .1%) had obesity, and 1291 women (68.3%) had central obesity.

11 al obesity, and WC and WHR, as indicators of central obesity.

12 hout central obesity, and 4) overweight with central obesity.

13 than 300 susceptibility loci associated with central obesity.

14 the genetic regulatory mechanisms underlying central obesity.

15 2 diabetes risk, especially among those with central obesity.

16 been shown to affect nutrient metabolism and central obesity.

17 excess adiposity is particularly related to central obesity.

18 causes osteoporosis, insulin resistance and central obesity.

19 on of body mass index (BMI) with measures of central obesity.

20 adiposity that combined BMI with measures of central obesity.

21 3.7% were overweight or obese, and 71.4% had central obesity.

22 year 5 and 1.44 (1.10, 1.88) for year 9] and central obesity [1.28 (1.02, 1.60) for year 5 and 1.62 (

23 roups were derived: 1) normal weight without central obesity, 2) normal weight with central obesity,

24 thout central obesity, 2) normal weight with central obesity, 3) overweight without central obesity,

25 (4.5-5.0) for obesity, 29.4% (28.9-29.9) for central obesity, 30.5% (30.0-31.0) for prediabetes, 5.1%

26 Central obesity (47.2%) and overweight (38.8%) in women

27 Women with normal-weight central obesity also had a higher mortality risk than th

28 xamine the effects of NPY variant rs16147 on central obesity and abdominal fat distribution in respon

29 he rs16147 single-nucleotide polymorphism on central obesity and abdominal fat distribution were modi

30 However, the pathophysiological link between central obesity and adverse cardiovascular outcomes rema

31 ediated primarily through a common link with central obesity and an expanded visceral fat mass.

32 We evaluated the association between central obesity and cardiac mechanics using multivariabl

33 phenotype similar to metabolic syndrome with central obesity and diabetes.

34 n the adipokine profile occur in parallel in central obesity and heart failure and are correlated wit

35 In this population-based cohort study, central obesity and higher adiposity were associated wit

36 we examined the associations of general and central obesity and hypertension among Chinese children.

37 o severe pediatric AD may be associated with central obesity and increased systolic BP.

38 pean whites and are accounted for by greater central obesity and insulin resistance in Indian Asians.

39 Recent studies have suggested that central obesity and insulin resistance may be primary me

40 tors but was eliminated by an adjustment for central obesity and insulin resistance score in Asians.

41 with MS and its components independently of central obesity and insulin resistance.

42 The rapid rise in childhood central obesity and its cardiometabolic complications in

43 luate the association between general and/or central obesity and knee OA risk, a Cox proportional haz

44 We hypothesized that central obesity and larger WHR are independently associa

45 Insulin resistance, central obesity and lipid abnormalities such as high tri

46 ther ox-LDL mediates the association between central obesity and MS, and whether insulin resistance m

47 suggesting that HAART increases the risk of central obesity and osteoporosis.

48 To investigate the association between central obesity and outcomes following in-hospital cardi

49 obesity and WC) and African American women (central obesity and percentage trunk fat) but was invers

50 ometric indices have been proposed to assess central obesity and predict metabolic syndrome (MetS).

51 Our findings highlight the association of central obesity and related cardiometabolic phenotypes a

52 The relationship between central obesity and survival in community-dwelling adult

53 Central obesity and the accumulation of visceral fat are

54 iated medication use"; 27.1%), and class 4 ("central obesity and treated hypertension"; 26.4%).

55 In the general population, changes in central obesity and visceral adiposity are observed year

56 entral adiposity among African American men (central obesity and WC) and African American women (cent

57 otion abnormalities, and ejection fraction), central obesity and WHR remained associated with worse g

58 it is unknown whether AD is associated with central obesity and/or high BP.

59 biological link between obesity (especially central obesity) and increased cancer risk.

60 with central obesity, 3) overweight without central obesity, and 4) overweight with central obesity.

61 tness (VO(2peak)), type of cancer treatment, central obesity, and depression to interleukin (IL)-6, I

62 t can be associated with excess weight gain, central obesity, and dyslipidemia.

63 a, low high-density lipoprotein cholesterol, central obesity, and elevated fasting glucose.

64 t disorders of lipid and glucose metabolism, central obesity, and high blood pressure, with an increa

65 The prevalence of general obesity, central obesity, and hypertension among the children was

66 The prevalence of general obesity, central obesity, and hypertension was high among Chinese

67 Prior chemotherapy, higher central obesity, and lower VO(2peak) were associated wit

68 onally representative indicators of obesity, central obesity, and MetS among US adults were construct

69 ts and their related nutrients with obesity, central obesity, and MetS, and attempted to explain some

70 overactivity is also known to be present in central obesity, and recent findings demonstrate the con

71 ors include gastroesophageal reflux disease, central obesity, and smoking.

72 g's syndrome, results in insulin resistance, central obesity, and symptoms similar to the metabolic s

73 evaluate the association between general and central obesity, and their changes with risk of knee ost

74 , 95% confidence interval (CI): 1.08, 1.35), central obesity (aPR = 1.11, 95% CI: 1.04, 1.19), and di

75 Weight gain and central obesity are associated with insulin resistance,

76 In summary, overall and central obesity are risk factors for COVID-19 hospital a

77 cording to the results of the current study, central obesity as determined by WC and citrus fruit int

78 Anthropometric measures of overall and central obesity as predictors of NIDDM risk have not bee

79 Central obesity assessed by waist-to-hip ratio was more

80 d increased waist-circumference, a marker of central obesity, associated with increased kynurenine, a

81 For women, central obesity, asthma, and arthritis increased the odd

82 02+/-17 cm, WHR was 0.91+/-0.08, and 80% had central obesity based on waist circumference and WHR cri

83 D, including those with normal and high BMI, central obesity but not BMI is directly associated with

84 ing to diabetes, hypertension, osteoporosis, central obesity, cardiovascular morbidity, and increased

85 y associated with PCOS only among women with central obesity (chi(2) = 35.0, p < 0.001) and not for t

86 f MetS occurred (77.3%), and the presence of central obesity conferred the highest risk of developing

87 Normal-weight central obesity defined by WHR is associated with higher

88 Central obesity, defined by increased waist circumferenc

89 le intake, low physical activity, obesity or central obesity, diabetes, hypertension, and dyslipidaem

90 ingly prevalent and strongly associated with central obesity, dyslipidemia, and insulin resistance.

91 The metabolic syndrome is characterized by central obesity, dyslipidemia, elevated blood pressure,

92 0001) and 13.9%, 18.3%, 22.1%, and 24.9% for central obesity (estimated increase 0.78% per year, 0.76

93 Hyperglycemia and central obesity experienced the highest increase.

94 erent measures of adiposity-overall obesity, central obesity, fat mass (FM)-and diabetes status for H

95 ists of a myriad of abnormalities, including central obesity, glucose intolerance, dyslipidemia, and

96 z score >2, World Health Organization 2006), central obesity (> or = 90th percentile, third National

97 mple, a man with a normal BMI (22 kg/m2) and central obesity had greater total mortality risk than on

98 Individuals with both general with central obesity had the highest risk (HR 1.418, 95% CI 1

99 Persons with normal-weight central obesity had the worst long-term survival.

100 Individuals with normal weight central obesity had the worst long-term survival: a pers

101 in the SA pedigrees were older, had greater central obesity, had higher prevalence of the metabolic

102 However, the presence of central obesity has significantly associated with the pr

103 tality risk than one with similar BMI but no central obesity (hazard ratio [HR], 1.87 [95% CI, 1.53 t

104 who entered the MetS having a combination of central obesity, high blood pressure, and hyperglycemia

105 General obesity without central obesity (HR 1.281, 95% CI 1.270-1.292) and centr

106 hazard ratio [HR], 1.46; 95% CI, 1.02-2.09), central obesity (HR, 1.41; 95% CI, 1.01-1.98), diabetes

107 lity risk than those with similar BMI but no central obesity (HR, 1.48 [CI, 1.35 to 1.62]) and those

108 ifestations of glucocorticoid excess include central obesity, hyperglycaemia, dyslipidaemia, electrol

109 ance of early-onset coronary artery disease, central obesity, hypertension, and diabetes.

110 ors or phenotypes that include dyslipidemia, central obesity, hypertension, and hyperinsulinemia, and

111 rategies alone, were associated with reduced central obesity in children from high- and middle-income

112 nificantly with almost all other measures of central obesity in older and younger men and women.

113 ly affected by increasing body mass index or central obesity in OSA patients and in OSA-free subjects

114 ; and stunting, underweight, overweight, and central obesity in women.

115 and overall obesity, and to a lesser extent central obesity, in normal processes of growth and devel

116 The prevalence of overweight, obesity, and central obesity increased with age (all p<0.0001) and wa

117 Obesity and central obesity indicators were highly intercorrelated a

118 Most correlations between obesity and central obesity indicators were moderate to strong (0.40

119 ponents of the metabolic syndrome, including central obesity, insulin resistance, abnormal lipid prof

120 atients with hypothalamic damage may develop central obesity, insulin resistance, and hyperphagia.

121 CT is associated with sustained increases in central obesity, insulin resistance, dyslipidemia and bl

122 Metabolic syndrome is characterized by central obesity, insulin resistance, elevated blood pres

123 Central obesity is a leading health concern with a great

124 Central obesity is a major risk factor for heart failure

125 e waist circumferences (WCs) to determine if central obesity is associated with abnormalities that mi

126 Central obesity is associated with higher risk of develo

127 Central obesity is associated with intrasphincteric exte

128 In children, central obesity is associated with reduced odds of aller

129 In patients with CAD, normal weight with central obesity is associated with the highest risk of m

130 In contrast,central obesity is directly associated with mortality.

131 efore HFpEF becomes clinically manifest, and central obesity is present in >80% to 90% of patients wi

132 ased intraabdominal pressure associated with central obesity is the probable etiology of PTC, a condi

133 Obesity, especially central obesity, is a hereditable trait associated with

134 inding that waist circumference, a marker of central obesity, is associated with greater liver stiffn

135 Obesity, specifically central obesity, is highly associated with MSyn incidenc

136 WHtR, when used as a proxy measure for central obesity, is linearly associated with ischemic CV

137 lack an obvious predisposition to GERD (eg, central obesity, large hiatal hernia).

138 overall obesity in PD pathogenesis; however, central obesity may be associated with higher PD risk am

139 y to omental adipose tissue, suggesting that central obesity may reflect "Cushing's disease of the om

140 phenotype, defined by insulin resistance and central obesity, may play a critical role in LV remodeli

141 The main outcome was childhood central obesity measured using waist circumference (WC),

142 Our aim was to compare the effect of central obesity (measured by waist-to-height ratio, WHtR

143 Central obesity measures should be incorporated in child

144 Central obesity metrics, such as waist circumference (WC

145 hat interventions to improve diet and manage central obesity might be most effective between ages 48

146 Central obesity most accurately predicts asthma.

147 Central obesity, most commonly approximated by the waist

148 Normal weight central obesity (NWCO), a distinct phenotype of obesity

149 sociated with risk factors of CVD, including central obesity, obesity, type 2 diabetes mellitus, rais

150 ction fraction) in the general community; 3) central obesity or visceral adiposity is present in >95%

151 42]), general obesity (OR 1.78 [1.61-1.98]), central obesity (OR 1.29 [1.18-1.42]), diabetes mellitus

152 In the adjusted model, central obesity (OR = 1.88, 95%CI = 1.18, 3.01) and cons

153 ral obesity (OR = 1.77, 95%CI = 1.11, 2.81), central obesity (OR = 2.09, 95%CI = 1.46,3.01) and consu

154 95% confidence interval [CI]: 3.69-9.55) and central obesity (OR = 3.45, 95% CI: 2.27-5.23) were stro

155 Remarkably, the remission of general or central obesity over two years was associated with decre

156 ased fructose intake was associated with the central obesity (P = 0.01) and hyperglycemia (P < 0.001)

157 erweight (p<0.0001), obesity (p=0.0008), and central obesity (p<0.0001) were more prevalent in male m

158 y used anthropometric measures to indicate a central obesity pattern and an increased risk of cardiov

159 Although insulin resistance and central obesity play an important role in the pathogenes

160 Despite the recognition that central obesity plays a critical role in chronic disease

161 BACKGROUND & AIMS: Central obesity promotes gastroesophageal reflux, which

162 ible sets from trans-ethnic meta-analysis of central obesity provide more precise localizations of po

163 unclear, but one mechanism proposed is that central obesity raises intra-abdominal pressure, which i

164 Central obesity rather than BMI could be a more importan

165 e testing to 91.4% for the identification of central obesity (ratio of waist circumference to height

166 Central obesity-related anthropometric parameters were m

167 s and reduce their sedentary time to prevent central obesity-related asthma.

168 binding prioritized 20 key TFs mediating the central-obesity-relevant genetic regulatory network.

169 is BMI and WHR, as indicators of overall and central obesity respectively, were associated with late

170 rcumference (WC) are measures of general and central obesity, respectively, and both have been shown

171 95% CI: 1.34,1.63) in women with and without central obesity, respectively, on the multiplicative sca

172 ence (WC) were used to determine general and central obesity, respectively.

173 Central obesity results in a cluster of metabolic abnorm

174 Central obesity significantly increased total and BC-spe

175 pulations for identifying and characterizing central obesity susceptibility that may be ancestry-spec

176 More boys had general and central obesity than girls (15.2% vs. 6.9%; 27.4% vs. 11

177 , is not associated with the weight gain and central obesity that is commonly observed in postmenopau

178 is a possible mechanism in the pathway from central obesity to asthma.

179 lative macrocephaly, moderate short stature, central obesity, unprovoked aggressive outbursts, fine i

180 NHLBI definitions of central obesity (waist circumference > or = 88 cm for wo

181 Logistic analysis showed that central obesity (waist circumference (WC) above 90 cm in

182 parently healthy individuals and measures of central obesity [waist circumference (WC)] and overall o

183 s in women with both gallbladder disease and central obesity was 37% higher than expected (relative e

184 Central obesity was also associated with higher mortalit

185 The combination of general and central obesity was associated with a higher risk at sev

186 Similarly, central obesity was associated with increased odds of no

187 Central obesity was associated with mortality (hazard ra

188 Central obesity was associated with poor IHCA outcomes,

189 In children, central obesity was associated with reduced odds of alle

190 Central obesity was defined as a waist circumference gre

191 of participants with multiple comorbidities, central obesity was found to be associated with adverse

192 001), although in women, the proportion with central obesity was similar (p=0.50), and in men, the pr

193 A variable called "central obesity" was created on the basis of tertiles of

194 weight women (18.5 <= BMI < 25), women with central obesity (WC > 88 cm) had an increased risk compa

195 he present study found that both general and central obesity were associated with increased risk of k

196 We found that common indices of overall and central obesity were associated with increased risks of

197 Obesity and central obesity were common, and most of the children ha

198 Childhood overall and central obesity were defined as age- and sex-specific BM

199 with obesity and MS; and neither obesity nor central obesity were independently associated with the d

200 However, overweight, obesity and central obesity were more prevalent in male migrant work

201 Overweight, obesity, or central obesity were not associated with allergic rhinit

202 mates were consistently lower for those with central obesity when age and BMI were controlled for.

203 ls and high screen time increase the risk of central obesity, which leads to asthma development.

204 ata on the "Asian Indian phenotype" identify central obesity, which occurs at a lower body mass index

205 cle in 22 female and 17 male volunteers with central obesity whose age (mean +/- SD) was 51 +/- 9 yea

206 A fuller understanding of the biology of central obesity will require information regarding the g

207 Central obesity with cardiometabolic syndrome (CMS) is a

208 models examined associations of general and central obesity with hypertension, and between body mass

209 ion, but data addressing the relationship of central obesity with kidney disease in type 1 diabetes a

210 l obesity (HR 1.281, 95% CI 1.270-1.292) and central obesity without general obesity (HR 1.167, 95% C

211 esized that CAD patients with normal BMI but central obesity would have worse survival compared to in

212 es resulting in weight loss and reduction of central obesity would lessen the incidence and costs of